Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Equity Bancshares reports Q3 results on 13 October with the stock off 7% over the past month and options traders turning notably more defensive than at any point in recent memory.
The most striking development since the earlier convergence notes is that borrow costs have reversed sharply. Cost to borrow hit 1.78% on 1 October, the level that drove those prior articles. It has since collapsed back to 0.36%, down 25% on the week and 41% over the past month. That is the lowest reading in the 30-day history and sits well below the September range of 0.47% to 0.69%. Availability has simultaneously swung looser, rising 83% on the week to 3,235%, meaning there are roughly 32 shares available for every one currently borrowed. Short interest itself has drifted back slightly to 2.84% of free float, down 1.2% on the day but still up 21% over the past month. The borrow squeeze that briefly appeared on 1 October has unwound. What remains is a modest but growing short position in a deep and unconstrained lending pool.
Options positioning tells a different story. Put buying has accelerated to the most extreme level of the past year in relative terms. The put/call ratio closed at 0.15 on 6 October, more than double its 20-day average of 0.074 and 3.6 standard deviations above that mean. The 52-week high is 1.07, so the absolute ratio remains low. But the speed of the move is the signal: the PCR was running below 0.07 as recently as late September and has now more than doubled in under two weeks. Options traders are hedging into the print at a pace that has no precedent in the past year's data, even as the short-selling community has not meaningfully pressed its position.
The Street is cautious but not bearish. The consensus sits at Hold, with five analysts there and none on Outperform. The mean price target is $55.29, roughly 16% above the current $47.50, but that gap narrowed after Piper Sandler's Nathan Race downgraded to Neutral and cut his target from $60 to $52 on 2 October. That action was covered in detail in the prior notes. The remaining buyers, StoneX at $59 and Stephens at $59, anchor the bull case on the Lincoln Savings Bank merger: 5.1% EPS accretion in 2027, 7.5% in 2028, and expansion to $9.1 billion in pro forma assets. The bear case is the mirror image: integration risk on a target with elevated nonperforming assets, margin pressure, and the planned disposal of the LSXB fintech platform creating near-term disruption. The P/E has compressed to 8.8x over the past month, down nearly a full turn in 30 days, while the price-to-book of 1.04x sits close to par.
The FDIC call report data for Q2 2026, covering the period through June, shows net loans and leases up 50% on the prior year and total deposits up 48%. Both figures reflect the consolidation of acquired entities rather than pure organic growth, and the ORTEX Alt Data layer has not yet accumulated enough history to test whether this series leads the company's reported figures. It is useful balance-sheet colour ahead of the print, but not a leading indicator.
Two activist investors remain on the 13D register: Fergeson Capital with 9.88% of the class, and Patriot Financial Partners with 4.85%. Both filings pre-date the Lincoln deal announcement. As required by SEC rules, those stakes are as last disclosed around the 5% threshold, and either holder could have moved without filing again. T. Rowe Price, the largest institutional shareholder at 11.5% of shares, added 272,000 shares in the quarter through June. On the insider side, director Donald Rogerson made two open-market purchases in July and August at $50 to $50.25 per share, each for $100,000. At the current price of $47.50 those trades are modestly underwater, but the buying was discretionary and unplanned.
With earnings six days away, the question is whether the options defensiveness proves well-founded or fades after a clean Q3 print. The prior three results have all produced positive next-day moves, ranging from 0.7% to 5.2%, but that record was set before the Lincoln deal entered its critical integration phase.
See the live data behind this article on ORTEX.
Open EQBK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
